Drugs and the Future

Drugs and the Future presents 13 reviews collected to present the new advances in all areas of addiction research, including knowledge gained from mapping the human genome, the improved understanding of brain pathways and functions that are stimulated by addictive drugs, experimental and clinical psychology approaches to addiction and treatment, as well as both ethical considerations and social policy. The book also includes chapters on the history of addictive substances and some personal narratives of addiction. Introduced by Sir David King, Science Advisory to the UK Government and head of the Office of Science and Technology, and Nora Volkow, director of the National Institute on Drug Abuse in the USA, the book uniquely covers the full range of disciplines which can provide insight into the future of addiction, from genetics to the humanities. Written for a scientific audience, it is also applicable to non-specialists as well. Provides an unique overview of what we know about addiction, and how scientific knowledge can and should be applied in the societal, ethical, and political context Applies the state-of-the-art research in fields such as Genomics, Neuroscience, Pharmacology, Social Policy and Ethics to addiction research Includes a preface by Sir David King, Science Advisory to the UK Government and head of the Office of Science and Technology, and in introduction by Nora Volkow, director of the National Institute on Drug Abuse in the USA

The Future of Drug Discovery: Who decides which diseases to treat? provides a timely and detailed look at the efforts of the pharmaceutical industry and how they relate, or should relate, to societal needs. The authors posit that as a result of increasing risk aversion and accelerated savings in research and development, the industry is not developing drugs for increasingly prevalent diseases, such as Alzheimer’s disease, untreatable pain, antibiotics and more. This book carefully exposes the gap between the medicines and therapies we need and the current business path. By analyzing the situation and discussing prospects for the next decade, the The Future of Drug Discovery is a timely book for all those who care about the development needs for drugs for disease. Provides an in-depth, broad perspective on the crisis in drug industry Exposes the disconnect between what society needs and what the drug companies are working on Analyses and projects over 10 years into the future Explains what it means for scientists and society Determines what is needed to be done to make sure that the industry responds to society's needs, remains commercially attractive and answers the question as to who decides which diseases to treat

A sweeping and highly readable work on the evolution of America’s domestic and global drug war How can the United States chart a path forward in the war on drugs? In Drugs and Thugs, Russell Crandall uncovers the full history of this war that has lasted more than a century. As a scholar and a high-level national security advisor to both the George W. Bush and Obama administrations, he provides an essential view of the economic, political, and human impacts of U.S. drug policies. Backed by extensive research, lucid and unbiased analysis of policy, and his own personal experiences, Crandall takes readers from Afghanistan to Colombia, to Peru and Mexico, to Miami International Airport and the border crossing between El Paso and Juarez to trace the complex social networks that make up the drug trade and drug consumption. Through historically driven stories, Crandall reveals how the war on drugs has evolved to address mass incarceration, the opioid epidemic, the legalization and medical use of marijuana, and America’s shifting foreign policy.

What if there were a pill for love? Or an anti-love drug, designed to help us break up? This controversial and timely new book argues that recent medical advances have brought chemical control of our romantic lives well within our grasp. Substances affecting love and relationships, whether prescribed by doctors or even illicitly administered, are not some far-off speculation – indeed our most intimate connections are already being influenced by pills we take for other purposes, such as antidepressants. Treatments involving certain psychoactive substances, including MDMA—the active ingredient in Ecstasy—might soon exist to encourage feelings of love and help ordinary couples work through relationship difficulties. Others may ease a breakup or soothe feelings of rejection. Such substances could have transformative implications for how we think about and experience love. This brilliant intervention into the debate builds a case for conducting further research into "love drugs" and "anti-love drugs" and explores their ethical implications for individuals and society. Rich in anecdotal evidence and case-studies, the book offers a highly readable insight into a cutting-edge field of medical research that could have profound effects on us all. Will relationships be the same in the future? Will we still marry? It may be up to you to decide whether you want a chemical romance.

In the wake of publicity and congressional attention to drug safety issues, the Food and Drug Administration (FDA) requested the Institute of Medicine assess the drug safety system. The committee reported that a lack of clear regulatory authority, chronic underfunding, organizational problems, and a scarcity of post-approval data about drugs' risks and benefits have hampered the FDA's ability to evaluate and address the safety of prescription drugs after they have reached the market. Noting that resources and therefore efforts to monitor medications' riskâ€"benefit profiles taper off after approval, The Future of Drug Safety offers a broad set of recommendations to ensure that consideration of safety extends from before product approval through the entire time the product is marketed and used.

About half of all species under threat of extinction in the world today are plants. The loss of plant biodiversity is disturbing for many reasons, but especially because it is a reflection of the growing disconnect between humans and nature. Plants have been used for millennia in traditional systems of healing and have held a significant place in drug development for Western medicine as well. Despite the recent dominance of synthetic drug production, natural product discovery remains the backbone of drug development. As the diversity of life on Earth is depleted and increasing numbers of species become lost to extinction, we continue to lose opportunities to achieve advances in medicine. Through stories of drug revelation in nature and forays into botany, human behavior, and conservation, Kara Rogers sheds light on the multiple ways in which humans, medicine, and plants are interconnected. With accessible and engaging writing, she explores the relationships between humans and plants, relating the stories of plant hunters of centuries past and examining the impact of human activities on the environment and the world's biodiversity. Rogers also highlights the role that plant-based products can play in encouraging conservation and protecting the heritage and knowledge of indigenous peoples. Out of Nature provides a fresh perspective on modern drug innovation and its relationship with nature. The book delves into the complexity of biophilia--the innate human attraction to life in the natural world--and suggests that the reawakening of this drive is fundamental to expanding conservation efforts and improving medicine. Rogers's examination of plants, humans, and drug discovery also conveys a passionate optimism for the future of biodiversity and medicine. Including a collection of hand-drawn maps and plant illustrations created by the author, this well-researched narrative will inspire as well as inform.

The Future of Pharmaceutical Product Development and Research examines the latest developments in the pharmaceutical sciences, also highlighting key developments, research and future opportunities. Written by experts in the field, this volume in the Advances in Pharmaceutical Product Development and Research series deepens our understanding of the product development phase of drug discovery and drug development. Each chapter covers fundamental principles, advanced methodologies and technologies employed by pharmaceutical scientists, researchers and the pharmaceutical industry. The book focuses on excipients, radiopharmaceuticals, and how manufacturing should be conducted in an environment that follows Good Manufacturing Practice (GMP) guidelines. Researchers and students will find this book to be a comprehensive resource for those working in, and studying, pharmaceuticals, cosmetics, biotechnology, foods and related industries. Provides an overview of practical information for clinical trials Outlines how to ensure an environment that follows Good Manufacturing Practice (GMP) Examines recent developments and suggests future directions for drug production methods and techniques

This book highlights the importance of traditional medicines, focuses on the standardization of herbal medicine and evaluates opportunities for advancing drug research. It addresses issues in utilization of medicinal plants and shares the importance of herbs in neutraceutics. It provides most competitive techniques being used in research.

Love drugs and anti-love drugs exist and more powerful versions will be available in the near future: What are the ethics of using them, how will they affect society, and will they take the magic out of love?

The Future of Pharmaceutical Product Development and Research examines the latest developments in the pharmaceutical sciences, also highlighting key developments, research and future opportunities. Written by experts in the field, this volume in the Advances in Pharmaceutical Product Development and Research series deepens our understanding of the product development phase of drug discovery and drug development. Each chapter covers fundamental principles, advanced methodologies and technologies employed by pharmaceutical scientists, researchers and the pharmaceutical industry. The book focuses on excipients, radiopharmaceuticals, and how manufacturing should be conducted in an environment that follows Good Manufacturing Practice (GMP) guidelines. Researchers and students will find this book to be a comprehensive resource for those working in, and studying, pharmaceuticals, cosmetics, biotechnology, foods and related industries. Provides an overview of practical information for clinical trials Outlines how to ensure an environment that follows Good Manufacturing Practice (GMP) Examines recent developments and suggests future directions for drug production methods and techniques

In 1860, Oliver Wendell Holmes pointedly expressed himself to the Massachusetts Medical Society: “I firmly believe that if the whole Material Medica, as now used, could be sunk to the bottom of the sea, it would be all the better for mankind, and all the worst for the fishes.” Should one think the same about the current approach in drug discovery from plants? Probably yes. Despite the spending of billions of US dollars, and three decades of efforts, high-throughput screenings have only allowed the discovery of a couple of drugs. One could have reasonably expected the discovery of an arsenal of drugs from the millions of plant extracts randomly tested, but “hits” can be inactive in vitro or too toxic, some molecules need to be metabolized first to be active, and false-positive and false-negative results are common. The bitter truth is that the robotic approach in discovering drugs from plants has proven, to date, its inability to excavate the hundreds of molecules that will contribute to the health progress of Man. However, one can reasonably see that the last patches of primary rainforest on earth hold still hundreds of spectacularly active drugs that await discovery.

Informed debate on how, why, or even if, drugs and those that use them should be controlled needs an insight into the background of such controls, how effective they have been and what reasonable alternatives there may be. This book seeks to provide such an insight. Reviewing important aspects of past and current drug control policies in Britain and America, the international compliment of expert contributors seek to explore the rationality of the reasoning which produced the initial controls, the continuing relevance of those currently employed, and provide alternative scenarios for future policy.

Deaths involving synthetic opioids, such as fentanyl, increased from roughly 3,000 in 2013 to more than 30,000 in 2018. This book provides readers with insights intended to improve their understanding of the synthetic opioid problem.

Drug Discovery Targeting Drug-Resistant Bacteria explores the status and possible future of developments in fighting drug-resistant bacteria. The book covers the majority of microbial diseases and the drugs targeting them. In addition, it discusses the potential targeting strategies and innovative approaches to address drug resistance. It brings together academic and industrial experts working on discovering and developing drugs targeting drug-resistant (DR) bacterial pathogens. New drugs active against drug-resistant pathogens are discussed, along with new strategies being used to discover molecules acting via new modes of action. In addition, alternative therapies such as peptides and phages are included. Pharmaceutical scientists, microbiologists, medical professionals, pathologists, researchers in the field of drug discovery, infectious diseases and microbial drug discovery both in academia and in industrial settings will find this book helpful. Written by scientists with extensive industrial experience in drug discovery Provides a balanced view of the field, including its challenges and future directions Includes a special chapter on the identification and development of drugs against pathogens which exhibit the potential to be used as weapons of war

Adverse Reactions to Drugs, Second Edition focuses on the problems posed by the adverse responses to drugs, as well as drug interactions, dosage, and drug metabolism. The publication first tackles adverse reactions and factors which predispose to adverse drug reactions. Topics include dose adjustment, overdose, renal failure, cumulation, side effects, drug allergy, cumulative overdose, and delayed effects. The text then ponders on drug interactions, including renal excretion, drug metabolism, mutual toxicity, and interactions affecting transport to site of action. The manuscript examines adverse reactions in dental practice, drugs used in pregnancy, the neonate, and lactation, and problems for the pharmaceutical industry before marketing a new drug. Discussions focus on ethical problems of drug studies in man, pregnancy, hemorrhage, oxygen toxicity, chloramphenicol, drugs and lactation, drugs used in dental practice, and local anesthetics. The book then elaborates on monitoring adverse reactions to drugs and the therapeutic audit and drug regulatory bodies and their problems. The publication is a valuable source of data for doctors and dentists wanting to focus on research on the adverse reaction to drugs.

This invaluable book provides a readable, introductory text to the fascinating subject of drug discovery from the medicinal plants of Asia-Pacific. A carefully designed layout presents more than 400 medicinal plants, and includes description of compound structure, molecular properties, pharmacology and clinical uses. With its broad scope and extensive compound listings, this is a premier reference source for natural products research using a pharmacological approach. Starting from a collection of plants in the rainforests of Asia-Pacific, Wiart shows how the present state of knowledge fosters a whole new way of looking at the discovery of drugs from medicinal plants.Wiart uses his approach to deal with a remarkable array of fundamental problems: from the phylogeny of plants, to the molecular basis of activity, limitations of phytochemistry, and the possibility of a truly fundamental theory of ethnopharmacology.Written with exceptional clarity, and illustrated by more than 300 original pictures and 400 chemical structures, this seminal book allows scientists and non-scientists alike to participate in what promises to be a major intellectual revolution.